The bisphosphonate pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in vitro

Anti-Cancer Drugs

Volumn 14, Issue 9, 2003, Pages 767-771

  Sonnemann, Jürgen ^a,b   Eckervogt, Vera ^a   Truckenbrod, Borna ^a   Boos, Joachim ^a   Winkelmann, Winfried ^a   Van Valen, Frans ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Bisphosphonates; Bone tumor; Clodronate; Ewing's sarcoma; Pamidronate; Statins

Indexed keywords

3 AMINOPROPANEPHOSPHONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; COMPACTIN; PAMIDRONIC ACID;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; EWING SARCOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; PRIORITY JOURNAL;

EID: 0242319830     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200310000-00013     Document Type: Article

References (24)

1. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19:80-100.
2. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000; 18:1378-1391.
3. Ashcroft AJ, Davies FE, Morgan GJ. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol 2003; 4:284-292.
4. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88:2961-2978.
5. Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog adenosine 5′-(β,μ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1996; 12:1358-1367.
6. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13:581-589.
7. van Seek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999; 264:108-111.
8. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000; 15:1467-1476.
9. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10:1478-1487.
10. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001; 12:459-465.
11. Paulussen M, Frohlich B, Jurgens H. Ewing tumour: incidence, prognosis and treatment options. Paediatr Drugs 2001; 3:899-913.
12. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976; 72: 323-326.
13. Shipman CM, Rogers MJ, Apperley JF, Russell RGR, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997; 98:665-672.
14. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82:1459-1468.
15. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602-2608.
16. Riebeling C, Forsea AM, Raisova M, Orfanos CE, Geilen CC. The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer 2002; 87:366-371.
17. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60:2949-2954.
18. Sawada K, Morishige K, Tahara M, Kawagishi R, Ikebuchi Y, Tasaka K, Murata Y. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res 2002; 62:6015-6020.
19. Leyvraz S, Hess U, Flesch G, Bauer J, Hauffe S, Ford JM, Burckhardt P. Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst 1992; 84:788-792.
20. Oiso Y, Tomita A, Hasegawa H, Ariyoshi Y, Niinomi M, Yamamoto M, et al. Pamidronate treatment with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics. Endocr J 1994; 41: 655-661.
21. Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997; 37:285-290.
22. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16:2038-2044.
23. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20:3219-3224.
24. Allgrove J. Use of bisphosphonates in children and adolescents. J Pediatr Endocrinol Metab 2002; 15:921-928.